Other formats:
BibTeX
LaTeX
RIS
@article{2368719,
author = {Vymazal, Josef and Kazda, Tomáš and Novak, Tomas and Slanina, Petr and Sroubek, Jan and Klener, Jan and Hrbac, Tomas and Syrucek, Martin and Rulseh, Aaron M M},
article_location = {LAUSANNE},
article_number = {January 2023},
doi = {http://dx.doi.org/10.3389/fonc.2022.1014455},
keywords = {glioblastoma; magnetic resonance imaging; survival; treatment; tumor treating field (TTF) therapy},
language = {eng},
issn = {2234-943X},
journal = {Frontiers in Oncology},
title = {Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma},
url = {https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1014455/full},
volume = {12},
year = {2023}
}
TY - JOUR
ID - 2368719
AU - Vymazal, Josef - Kazda, Tomáš - Novak, Tomas - Slanina, Petr - Sroubek, Jan - Klener, Jan - Hrbac, Tomas - Syrucek, Martin - Rulseh, Aaron M M
PY - 2023
TI - Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma
JF - Frontiers in Oncology
VL - 12
IS - January 2023
SP - 1-9
EP - 1-9
PB - FRONTIERS MEDIA SA
SN - 2234943X
KW - glioblastoma
KW - magnetic resonance imaging
KW - survival
KW - treatment
KW - tumor treating field (TTF) therapy
UR - https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1014455/full
N2 - IntroductionThe prognosis of glioblastoma remains unfavorable. TTFields utilize low intensity electric fields (frequency 150-300 kHz) that disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields are delivered via transducer arrays placed on the patients' scalp. Methods: Between the years 2004 and 2022, 55 patients (20 female), aged 21.9-77.8 years (mean age 47.3 +/- 11.8 years; median 47.6 years) were treated with TTFields for newly-diagnosed GBM, and compared to 54 control patients (20 females), aged 27.0-76.7 years (mean age 51.4 +/- 12.2 years; median 51.7 years) (p=0.08). All patients underwent gross total or partial resection of GBM. One patient had biopsy only. When available, MGMT promoter methylation status and IDH mutation was detected. ResultsPatients on TTFields therapy demonstrated improvements in PFS and OS relative to controls (hazard ratio: 0.64, p=0.031; and 0.61, p=0.028 respectively). TTFields average time on therapy was 74.8% (median 82%): median PFS of these patients was 19.75 months. Seven patients with TTFields usage <= 60% (23-60%, mean 46.3%, median 53%) had a median PFS of 7.95 months (p=0.0356). Control patients with no TTFields exposure had a median PFS of 12.45 months. Median OS of TTF patients was 31.67 months compared to 24.80 months for controls. DiscussionThis is the most extensive study on newly-diagnosed GBM patients treated with TTFields, covering a period of 18 years at a single center and presenting not only data from clinical trials but also a group of 36 patients treated with TTFields as a part of routine clinical practice.
ER -
VYMAZAL, Josef, Tomáš KAZDA, Tomas NOVAK, Petr SLANINA, Jan SROUBEK, Jan KLENER, Tomas HRBAC, Martin SYRUCEK and Aaron M M RULSEH. Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma. \textit{Frontiers in Oncology}. LAUSANNE: FRONTIERS MEDIA SA, 2023, vol.~12, January 2023, p.~1-9. ISSN~2234-943X. Available from: https://dx.doi.org/10.3389/fonc.2022.1014455.
|
